Dominari Holdings Inc. (NASDAQ:DOMH) Announces $0.31 Special Dividend

Key Points

• Dominari Holdings announced a special dividend of $0.31 per share; investors of record on May 15 will be paid on May 29 and the ex-dividend date is May 15.
• Shares rose about 5% to $3.15 on higher-than-average volume; the company is a ~ $71.2M market-cap biotech developing small-molecule anticancer and antiviral candidates but currently carries an average analyst rating of Sell after recent downgrades.

Dominari Holdings Inc. (NASDAQ:DOMH - Get Free Report) announced a special dividend on Monday, May 4th. Investors of record on Friday, May 15th will be given a dividend of 0.31 per share on Friday, May 29th. The ex-dividend date is Friday, May 15th.

Dominari Stock Up 5.0%

Shares of DOMH stock traded up $0.15 during mid-day trading on Monday, reaching $3.15. 158,262 shares of the company's stock traded hands, compared to its average volume of 132,054. Dominari has a 12 month low of $2.68 and a 12 month high of $8.40. The company has a market cap of $71.23 million, a P/E ratio of -0.81 and a beta of 0.69. The company's 50-day moving average price is $3.00 and its 200-day moving average price is $3.98.

Wall Street Analysts Forecast Growth

DOMH has been the topic of a number of research reports. Weiss Ratings cut shares of Dominari from a "hold (c-)" rating to a "sell (d+)" rating in a report on Monday, January 12th. Wall Street Zen cut shares of Dominari from a "hold" rating to a "sell" rating in a report on Saturday, April 18th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of "Sell".

Dominari Company Profile

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.